Related Experiment Video
Updated: Jul 25, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine
Chaitra Janga1, Tirth Patel1, Hussam Al Hennawi1
1Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA.
Abstract:
Myopericarditis associated with COVID-19 mRNA vaccines has been recognized as an uncommon adverse reaction, especially among young, healthy adult males. Eosinophilic myocarditis is a rare form of inflammation reflecting a hypersensitivity reaction following an inciting event commonly caused by drugs including vaccines. Eosinophilic myocarditis, a subtype of myocarditis, is characterized by eosinophilic myocardial infiltrates. It is usually accompanied by systemic eosinophilia in the form of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and is rarely associated with myocyte fibrosis and/or necrosis. In this report, we present a case of biopsy-proven eosinophilic myocarditis in a 24-year-old male patient, likely secondary to COVID-19 mRNA vaccination. To our knowledge, this is the first report to describe delayed eosinophilic myocarditis following the COVID-19 mRNA vaccine. Clinicians should be aware of possible delayed presentation to avoid associated morbidity.
Insights
Delayed eosinophilic myocarditis, a rare hypersensitivity reaction, can occur after COVID-19 mRNA vaccination. This case highlights a potential delayed presentation of this vaccine adverse event.
Area of Science:
- Cardiology
- Immunology
- Vaccinology
Background:
- Myopericarditis is an uncommon adverse reaction associated with COVID-19 mRNA vaccines, particularly in young males.
- Eosinophilic myocarditis, a rare subtype of myocarditis, involves myocardial eosinophilic infiltrates and can be a hypersensitivity reaction to drugs or vaccines.
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome may accompany eosinophilic myocarditis, which rarely involves myocyte necrosis or fibrosis.
Observation:
- A case report details a 24-year-old male experiencing biopsy-proven eosinophilic myocarditis.
- The patient's condition was likely a delayed adverse reaction following COVID-19 mRNA vaccination.
Findings:
- This case represents the first reported instance of delayed eosinophilic myocarditis post-COVID-19 mRNA vaccination.
- The patient presented with characteristic eosinophilic myocardial infiltrates.
Implications:
- Clinicians should consider the possibility of delayed eosinophilic myocarditis as a vaccine adverse event.
- Awareness of delayed presentations is crucial for timely diagnosis and management to prevent associated morbidity.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis IV: Nursing Management

